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Abstract
Patients suffering from chronic mountain sickness (CMS) exhibit extremely high haemoglobin
concentrations. Their haemoglobin mass (Hbmass), however, has rarely been investigated.
The CO-rebreathing protocol for Hbmass determination in those patients might need to be
modified because of restricted peripheral perfusion. The aim of this study was to evaluate the CO
uptake and carboxyhaemoglobin-mixing time in the blood of CMS patients and to adapt the CO-
rebreathing method for this group. Twenty-five male CMS patients living at elevations between
3600 and 4100 m above sea level were compared with ethnically matched healthy control
subjects from identical elevations (n = 11) and near sea level (n = 9) and with a Caucasian group
from sea level (n= 6). CO rebreathing was performed for 2min, and blood samples were taken for
the subsequent 30min. After themethodwasmodified, its reliability was evaluated in test–retest
experiments (n = 28), and validity was investigated by measuring the Hbmass before and after
the phlebotomy of 500 ml (n = 4). CO uptake was not affected by CMS. The carboxyhaemoglobin
mixing was completed after 8 min in the Caucasian group but after 14 min in the groups living
at altitude. When blood was sampled 14–20 min after inhalation, the typical error of the method
was 1.6% (confidence limits 1.2–2.5%). After phlebotomy, Hbmass decreased from 1779 ± 123
to 1650 ± 129 g, and no difference was found between the measured and calculated Hbmass
(1666 ± 122 g). When the time of blood sampling was adapted to accommodate a prolonged
carboxyhaemoglobin-mixing time, the CO-rebreathing method became a reliable and valid tool
to determine Hbmass in CMS patients.
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1 INTRODUCTION
In clinical practice and in the field of sports medicine, the optimized
CO-rebreathing method (oCOR method; Gore et al., 2006; Prommer
& Schmidt, 2007; Schmidt & Prommer, 2005) is used to determine
the total haemoglobin mass (Hbmass). In comparison to previously
performed dilution techniques using radioactive markers (e.g. 32P,
99mTC, 59Fe, 51Cr) or dye markers, such as Evans Blue (Gibson &
Evans, 1937), hydroxyethyl starch (Tschaikowsky, Meisner, Durst,
& Rügheimer, 1997) or Indocyanine Green (He, Tanigami, Ueyama,
Mashimo, & Yoshiya, 1998), the oCOR method is less invasive and
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easier to apply (Turner et al., 2014). The main differences compared
with previous CO-rebreathing methods are a reduced rebreathing
time of 2 min in a custom-made spirometer, fewer acquired blood
samples and the possibility of using capillary blood (Schmidt &
Prommer, 2005). The oCORmethod is well tolerated by young trained
athletes and by older subjects and patients (Ahlgrim, Schumacher,
Wrobel, Waller, & Pottgiesser, 2014; Otto et al., 2017; Wachsmuth
et al., 2013).
Prerequisites of the method are unrestricted diffusion of CO from
the lung to the blood, the complete mixing of CO in the blood, and
knowledge of the volumes of CO that have diffused out of the blood
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and bound to myoglobin or been exhaled via respiration (Garvican
et al., 2010; Schmidt & Prommer, 2005). When applying the oCOR
method to healthy subjects, these prerequisites are all fulfilled.
In some groups of patients, however, these preconditions are not
guaranteed, e.g. in patients with chronic obstructive pulmonary
disease, in patients with disturbances in peripheral arterial perfusion
and in polycythaemia vera (Ahlgrim et al., 2014). Before applying the
CO-rebreathing method to these patients, the above factors have to
be verified, and themethodmight need to bemodified.
Patients with chronic mountain sickness (CMS) or Monge’s disease
(Monge, 1942; Monge & Whittembury, 1976) are characterized by
severe polycythaemia [concentration of haemoglobin ([Hb])>19 g dl−1
for women and>21 g dl−1 for men; León-Velarde et al., 2005; Vásquez
& Villena, 2001; Villafuerte & Corante, 2016}. The disease occurs at
elevations >2500 m above sea level (a.s.l.; León-Velarde et al., 2005;
Villafuerte&Corante, 2016), and it is supposed that peripheral chemo-
receptors are desensitized and that the impaired breathing stimulus
results in hypoventilation and reduced arterial partial pressure of O2
and oxygen saturation of haemoglobin (SO2 ; León-Velarde & Richalet,
2006; Severinghaus, Bainton, & Carcelen, 1966). This outcome results
in excessive erythropoiesis, leading to augmented red cell mass and
blood viscosity (Kwaan & Wang, 2003). Significant symptoms are
vascular dysfunction (Rimoldi et al., 2012), reduced cerebral blood
flow velocity (Claydon et al., 2005), increased pulmonary blood
pressure (Maignan et al., 2009) and cardiac failure (León-Velarde et al.,
2005; Villafuerte & Corante, 2016). Therefore, it seems possible that
when the CO-rebreathing method is applied to these patients, the
mixing time of the COmarker in the bloodmight be prolonged.
In general, the [Hb] and haematocrit (Hct) depend on the Hbmass
or red cell volume and the magnitude of plasma volume. In patients
suffering from CMS, the size of the blood compartments is rarely
investigated. There exists only one study of 11 CMS patients from
4350 ma.s.l. using Evans Blue for the determination of plasma
volume (Claydon et al., 2004). Those authors described an almost
normal plasma volume and calculated a massively increased red cell
volume compared with healthy high-altitude residents. Although their
study provided valuable information, there were some limitations
influencing the validity of the data. The results were obtained from
a small group of patients, and the red cell volume was determined
indirectly, bymeasuring the plasma volume and calculating the red cell
volume. Given that the cell factor describing the different distribution
of cell mass and plasma in peripheral and central blood may change
at altitude (Sánchez, Merino, & Figallo, 1970), direct measurements
of Hbmass and/or red cell volume should be used. Exact Hbmass data
would be valuable for quantifying the amount of haemoglobin and
distinguishing between haemoconcentration attributable to reduced
plasma volume and haemoconcentration attributable solely to an
enhanced erythrocyte volume.
When applying the oCOR method for healthy subjects to CMS
patients, the altered haemodynamics will probably affect the mixing
time for the administered CO, leading to inaccurate or even false
results. It is therefore mandatory to determine the exact mixing time
to adjust the time points for blood sampling (Ahlgrim et al., 2014) and
NewFindings
• What is the central question of this study?
Is it necessary to modify the CO-rebreathing method to
acquire reliable measurements of haemoglobin mass in
patients with chronic mountain sickness?
• What is themain finding and its importance?
The CO-rebreathing method must be modified because
of the prolonged CO-mixing time in patients with
chronic mountain sickness. After adaptation of the
blood sampling method, reliable and valid results were
attained. With this modification, it is possible to quantify
the extent of polycythaemia and to distinguish between
a haemoconcentration and an exclusive enhancement of
erythrocyte volume.
to examine the amount of CO taken up by the blood and the amount of
CO that diffuses from blood tomyoglobin.
Additionally, the CO uptake during the rebreathing period might
be altered, as can be assumed from the delayed CO uptake (Herbert
et al., 1965),microembolisms inpulmonaryarteries (Arias-Stella, 1971;
Burgess & Bishop, 1963) and elevated blood volume in the pulmonary
vascular bed (Greening, Patel, Goolden, Munro, & Hughes, 1982)
observed in patients suffering from polycythaemia vera. In addition, a
third source of error might be the loss of CO owing to diffusion from
the vascular bed to myoglobin, which must be quantified, especially in
CMS patients, for whom no related data are available.
The aim of the study was therefore to evaluate and, if necessary, to
adapt the currently used CO-rebreathing method to be used in CMS
patients. We analysed the optimal time points for blood sampling, we
checked the extraction of CO from the lung and determined the loss
of CO from blood to myoglobin. With the information obtained, we
modified the CO-rebreathing method and demonstrated its reliability
and validity for CMS patients.
2 METHODS
2.1 Ethical approval
The subjects were informed about the requirements and possible risks
of the study before giving written consent to participate. The subjects
volunteered to participate in the study and were free to withdraw at
any timewithout needing to provide a reason. The study conformed to
the standards set by the Declaration of Helsinki, except for registration
in a database. The study was approved by the Ethics Committee of the
UniversidadMayor San Andres in La Paz, Bolivia.
2.2 Subjects
In total, 51 male subjects participated in the study. Twenty-one of
the subjects lived at high altitude (between 3600 and 4100 m a.s.l.)
and were classified as CMS patients. Another four subjects living at
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TABLE 1 Subject characteristics
Subject group
Altitude of residence
(m a.s.l.) n Age (years) Height (cm) Weight (kg) BMI (kgm−2) Hct (%) [Hb] (g dl−1)
CMS patients 3600–4100 21 56.9± 8.8 166.1± 6.2 84.6± 10.5 30.7± 3.5 67.8± 3.5 21.8± 1.1
Intermediates 3600–4100 4 42.0± 17.8 166.6± 3.5 77.2± 17.0 27.9± 6.6 60.8± 3.0 19.3± 0.3
Controls-LP 3600–4100 11 43.2± 15.6 163.6± 6.8 76.4± 11.1 28.6± 4.4 51.7± 3.2 17.0± 0.9
Controls-SZ 300–500 9 47.8± 16.2 166.2± 8.8 73.6± 13.4 26.8± 5.6 46.1± 2.9 14.6± 0.8
Controls-BT 300–500 6 24.5± 4.2 180.7± 6.5 75.1± 6.1 23.0± 1.3 – 15.3± 1.4
Values are presented as means ± SD. Abbreviations: a.s.l., above sea level; BMI, body mass index; BT, Bayreuth; Hct, haematocrit; LP, La Paz; and SZ, Santa
Cruz.
the same altitude who did not completely fulfil the criteria for CMS
were classified as ‘intermediates’. Twenty-six subjects without CMS
symptoms were recruited as control subjects; 11 of the them lived at
the same altitude as the CMS patients (Controls-LP). Another 15 sub-
jects lived near sea level; nine had moved from altitude >2 years ago
(Controls-SZ), and six were native sea-level dwellers (Controls-BT).
Some of the subjects participated in various parts of this study. The
characteristics of the participants are presented in Table 1.
2.3 Study design
The project was divided into two substudies. The first part of the
project dealt with the determination of the optimal blood sampling
time points, which might differ from the known oCOR method owing
to the possibly delayed CO mixing in CMS patients. The prerequisite
for this calculation is knowledge about the amount of CO that diffuses
fromtheblood tomyoglobin and theamountofCOthat is exhaledafter
disconnection of the subject from the spirometer. Taking these factors
into account, we calculated the Hbmass every 2 min until 20 min and
then every 5 min until 30 min after inhalation of the CO bolus. When
the calculated Hbmass values reached a plateau, the CO mixing in
blood was assumed to be complete. Based on these data, the time
points for blood sampling weremodified.
In the second part of the project, the reliability of the modified CO-
rebreathing method was calculated by performing test–retests and
calculating the typical error of the method. Furthermore, the validity
of the method was determined by measuring the Hbmass before and
after withdrawal of ∼500 ml of blood. The distribution of the subjects
to the different substudies is illustrated in Table 2.
2.4 Part I: Modification of the CO-rebreathing
method
Haemoglobinmasswasmeasured using the optimizedCO-rebreathing
method (Gore et al., 2006; Prommer & Schmidt, 2007; Schmidt
& Prommer, 2005) with modifications concerning blood sampling
and measurements of the end-tidal CO concentration. A CO bolus
followed by 3.5 l of pure oxygen was rebreathed through a glass
spirometer (SpiCo, Bayreuth, Germany) for 2 min. The volume of CO
administered was adjusted to altitude according to the barometric
pressure and to the expected value of Hbmass. The CO bolus for the
control subjects from sea level (SZ and BT) was calculated as 1.0 ml
(kg body mass)−1. For all measurements at altitude (3600 m a.s.l.),
TABLE 2 Participants in the substudies
Part I Part II
Subject group
Modification of
themethod Reliability Validity
CMS patients 9 19 4
Intermediates − 4 −
Controls-LP 11 5 −
Controls-SZ 9 − −
Controls-BT 6 − −
Total 35 28 4
Abbreviations: BT, Bayreuth; CMS, chronic mountain sickness; LP, La Paz;
and SZ, Santa Cruz.
the decrease in barometric pressure (∼500 mmHg) was considered.
Given that Hbmass is ∼20% higher in natives to high altitude than
in subjects from sea level (Heinicke et al., 2003), the CO bolus was
increased to 1.5 ml (kg body mass)−1 in the control subjects from
altitude (LP). For CMS patients and intermediates, the CO bolus was
calculated according to the measurements in a pilot study as 1.7 ml
(kg body mass)−1. In overweight subjects, the theoretically derived
body mass corresponding to a body mass index of 25 kg m−2 was
used for the calculation. Capillary blood was sampled from an earlobe
three times before and once every second minute after starting the
rebreathing period until the 20 min mark and at the 25 and 30 min
marks. From each blood sample, three replicates were analysed for
carboxyhaemoglobin (COHb) using a CO haemoximeter (OSM3;
Radiometer, Copenhagen, Denmark).
To calculate the amount of CO not taken up during the inhalation, a
CO analyser (Draeger, Luebeck, Germany) was used to determine the
CO remaining in the spirometer system. Additionally, the end-tidal CO
concentration was measured 2, 6, 13 and 23 min after disconnecting
the subject from the spirometer. Owing to the hyperventilation at
altitude, the alveolar ventilation of controls-LP was adjusted by 10%
(Hultgren, 1997). This adjustment was not performed for the CMS
patients owing to the lack of increased hypoxic ventilation (Villafuerte
& Corante, 2016). Unlike the Bolivian subjects, in controls-BT, the
volume and the CO concentration of exhaled air were measured
continuously after CO rebreathing up to 30 min. The Hbmass was
determined using the following formula (Equation 1):
Hbmass (in grams) = K ×MCO × 100(ΔCOHb% × 1.39)−1 (1)
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Where K = current barometric pressure × 760−1 × [1(0.003661 ×
current temperature)]; MCO = COadm − (COsystem+lung after disconnection
+ COexhaled after disconnection) −MHb; COadm = CO volume administered
into the system; COsystem+lung after disconnection = CO concentration
in the spirometer × (spirometer volume + lung residual volume);
COexhaled after disconnection = Δend-tidal CO concentration × alveolar
ventilation × time; MHb = CO diffusing to myoglobin; ΔCOHb% =
difference between basal COHb% and COHb% in the blood samples
after CO administration; and 1.39 = Hüfner’s number (in millilitres
of CO per gram of Hb; e.g. Gorelov, 2004). The Hbmass values were
calculated every second minute until 20 min and at 25 and 30 min.
To quantify the diffusion of CO from blood to myoglobin, three
different factors were used. We assumed that in the case of the best-
fitting factor, the most constant plateau of Hbmass was achieved. The
following three formulae (Equations 2–4) for calculating CO diffusion
tomyoglobin were used to verify the appropriate correction factor:
MHb0.002 = 0.002 × time × CO administered
(Schmidt& Prommer,2005), (2)
MHb0.003 = 0.003 × time × COadministered
(Prommer& Schmidt,2007); (3)
MHbCHA = [(0.091 × time) + (0.013 × CO administered)]
(Chada&Bruce,2012). (4)
When using OSM3 (Radiometer, Denmark) to analyse
blood samples, one must take into account that percentage
carboxyhaemoglobin (COHb%) values also depend on the SO2 (Hütler,
Beneke, Littschwager, & Böning, 2001). The majority of the tests were
performed at high altitude, where the SO2 in arterialized blood is
reduced. After inhaling 3.5 l of pure oxygen during the rebreathing
procedure, the SO2 increases,which requires anadjustment inCOHb%.
We used an individual correction factor for every subject according
to the recommendations of Hütler et al. (2001): venous (see next
paragraph) and capillary blood samples were taken simultaneously
before the CO-rebreathing test and were analysed for COHb% and
SO2 , and a correction factor for the real COHb% in the main test was
obtained (see Equation 5):
Factor COHb = (COHb%capillary
−COHb%venous)∕(SO2 capillary − SO2 venous )
(5)
To determine the [Hb] and Hct, venous blood samples were drawn
into an EDTA tube from a cubital vein after the subject had been
sitting for ≥10 min and after the tourniquet was removed. The [Hb]
wasmeasured spectrophotometrically using the cyanmethaemoglobin
method, and theHctwasmeasuredby themicrohaematocrit technique
at 12,000 r.p.m. for 5min.
2.5 Part II: Reliability and validity of themodified
method
To determine the reliability of the modified CO-rebreathing method,
test–retests were performed. Based on the results of part I, the time
points of blood sampling were set at 14, 16, 18 and 20 min, and the
mean COHb value of this period was used for further calculations. The
end-tidal CO concentration was measured before the tests and at 2,
6 and 13 min after disconnecting the subject from the spirometer. To
calculate the amount of CO diffusing to myoglobin, the best-fitting
factor from part I, i.e. 0.002mlmin−1, was used.
The validity of themodified CO-rebreathingmethodwas evaluated
by measuring Hbmass immediately before and after withdrawal of
∼500 ml blood with subsequent fluid replacement. The Hbmass was
determined as described in section 2.4. The transfusion bag, including
the tubes for collecting the blood, was weighed before and after the
blood withdrawal, and a blood sample was taken from the transfusion
bag to determine the [Hb]. The Hbmass in the bag was calculated
according to the following formula (Equation 6):
Hbmass in transfusion bag = (weight of transfusion bag after
−weight of transfusion bag before)
× specific weight for blood (1.07g ml−1) ×
[
Hb
]
∕100 (6)
2.6 Statistics
Data are presented as the mean value ± SD. Student’s paired t tests
were applied to compare possible differences between the time points
of blood sampling and between the three calculation possibilities for
Hbmass by using the different equations for CO diffusion to myo-
globin (Hopkins, 2003). Furthermore, Student’s paired t tests were
used to compare the Hbmass values calculated for different mixing
times, i.e. according to the established oCOR method (second blood
sample at minute 6 + 8; Prommer & Schmidt, 2007) and the period of
completemixing obtained in this study (14–20min). Another Student’s
paired t test was performed to compare the calculated and measured
Hbmass lost after the blood withdrawal, which was performed
to check the validity of the method. An ANOVA with repeated
measurements was carried out to detect effects of group × time
interactions for the COHb kinetics after the CO bolus inhalation.
When the outcomes of the ANOVA were significant (P < 0.05),
Scheffé’s tests were used to compare the individual groups with one
another.
The typical error (TE) of the modified method was calculated
according to Hopkins (2000). A correlation analysis was performed
to check the reliability of the modified method by evaluating the
relationship of Hbmass obtained in the test and retest.
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F IGURE 1 Carboxyhaemoglobin (COHb) kinetics during and up to
28min after the CO-rebreathing protocols. The absolute differences
from baseline values (a) and the percentage decrease from the peak
value observed at minute 1 (b) are shown. Abbreviations: BT,
Bayreuth; CMS, chronic mountain sickness; LP, La Paz; and SZ, Santa
Cruz. ANOVA and post hoc tests (Scheffé’s test) yielded significant
differences in the percentage decrease between Controls-BT and
CMS patients (P< 0.01) and Controls-LP (P< 0.05)
3 RESULTS
3.1 Part I: Modification of the CO-rebreathing
method
In all groups, peakvalues forCOHbconcentrationwereobserved1min
after CO bolus inhalation (Figure 1a). Thereafter, the decline in COHb
showed clear effects of a treatment × time interaction (P < 0.01),
and post hoc tests (Scheffé’s tests) yielded significant differences
between Controls-BT and CMS (P < 0.01) and Controls-LP (P < 0.05)
(Figure 1b). Furthermore, we compared the CO content remaining
in the spirometer after disconnection of the test subject to evaluate
possible diffusion limitations. As demonstrated in Table 3, there were
normal amounts of CO left in all groups, and in the spirometer of CMS
patients theCOconcentrationwaseven lower than that of control sub-
jects from La Paz and Santa Cruz.
3.1.1 CO diffusion tomyoglobin
Calculation of Hbmass with the three different correction factors
yielded an almost identical time course of the values until 12 min
after inhalation of the CO bolus. As time passed, the calculated
Hbmass decreased when using the factor MHb0.003, indicating a
non-realistically high diffusion rate, whereas the other two factors,
MHb0.002 and MHbCHA, resulted in an almost constant and similar
time course of Hbmass values over time. Given that there was a small
and non-significant tendency of MHbCHA to overestimate Hbmass in
the high-altitude groups, we decided to use the factor MHb0.002 for
all subsequent calculations of Hbmass because this factor yielded a
plateau from 14 to 30min in all four groups.
3.1.2 CO-mixing time in blood
The calculated Hbmass values in the four groups reached their
plateau at different time points after CO rebreathing. Controls-BT
achieved constantHbmass values after6min (Figure2a), andControls-
SZ achieved constant Hbmass values after 8 min (Figure 2b). No
significant differences from previous values were found thereafter.
In the subjects from high altitude, the time to reach the plateau was
delayed, and no significant difference from previous values was found
from 14 to 30 min (Figure 2c,d). Given that all four groups showed a
plateau between 14 and20min, blood samples from this period of time
were used to determine the real Hbmass.
Figure 3 illustrates the difference in Hbmass between the
conventionalmethod (Prommer&Schmidt, 2007; Schmidt&Prommer,
2005) using the mean COHb values at 6 and 8 min for the calculation
of Hbmass and the modified method, assuming a delayed mixing time,
as mentioned above. No differences in Hbmass were found in the
Controls-BT, whereas in all other groups, higher Hbmass values were
obtained with the modified method (blood sampling after 14–20 min)
than with the original method. The percentage differences were
4.4± 2.3% in Controls-SZ, 4.8± 1.9% in Controls-LP and 6.7± 2.5% in
CMS patients.
3.2 Parts II and III: Reliability and validity of the
modifiedmethod
Test–retests were performed using the modified method with 28
subjects from high altitude (control subjects and CMS patients; see
TABLE 3 [CO] remaining in the spirometer after CO rebreathing
CMS patients Controls-LP Controls-SZ Controls-BT
[CO] in spirometer (p.p.m.) 187± 89*† 284± 90 327± 123 235± 124
Values are presented as means ± SD. Abbreviations: BT, Bayreuth; LP, La Paz; and SZ, Santa Cruz. Significant differences in [CO] in the spirometer between
the groups: *P< 0.05 comparedwith Controls-LP and †P< 0.05 comparedwith Controls-SZ.
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F IGURE 2 Time course of the calculated haemoglobinmass (Hbmass) after CO rebreathing in subjects from sea level (a,b) and altitude (c) and
in CMS patients from La Paz (d). Presented aremean values and individual data of the Hbmass calculated for different time points of blood
sampling. Abbreviations: BT, Bayreuth; CMS, chronic mountain sickness; LP, La Paz; and SZ, Santa Cruz. Significant differences from previous
values: *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. The time period between 14 and 20min after CO inhalation that was used for the calculation of Hbmass
is marked by vertical lines
F IGURE 3 Differences in haemoglobinmass (Hbmass) using
different time points for blood sampling in subjects from sea level
(Controls-BT and Controls-SZ) and altitude (Controls-LP and the CMS
patients). Abbreviations: BT, Bayreuth; CMS, chronic mountain
sickness; LP, La Paz; and SZ, Santa Cruz. The difference between the
conventional andmodifiedmethods is presented. Significant
differences between themethods: ***P≤ 0.001
Table 2). The TE was 23.1 g (1.6%; confidence limits, 1.2–2.5%).
There was an excellent correlation between the test and retest
measurements of Hbmass (r= 0.995; P≤ 0.001; Figure 4).
In four CMS patients, Hbmass was measured before and after
withdrawal of 500 ml of blood, and the reduction in Hbmass was
compared with the reduction calculated from the [Hb] in the trans-
fusion bag. By this measure, Hbmass was reduced from 1779 ± 123 g
to 1650 ± 129 g (7.2 ± 1.6%; measured) or to 1666 ± 122 g
(6.3 ± 0.4%; calculated), and no difference between the two methods
of determination was found (Figure 5).
4 DISCUSSION
4.1 CO application and CO diffusion in the lungs
Owing to the lowambient pressure, the volumeof theCObolus inhaled
by the subjects at high altitude had to be increased by 35%. A further
increase of ∼20% was implemented for the control subjects from
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F IGURE 4 Correlation between test–retest measurements of
haemoglobinmass (Hbmass; r= 0.991; P≤ 0.001) by themodified
CO-rebreathingmethod. Abbreviations: CMS, chronic mountain
sickness; and LP, La Paz
high altitude because their Hbmass was expected to be augmented in
comparison to that of subjects from sea level (Heinicke et al., 2003).
Given that we did not want to expose the CMS patients to any risk,
we did not increase the CO volume to the extent (∼2.4 ml kg−1) that
would yield COHb concentrations matching those in the control sub-
jects. The CMS patients, therefore, received CO at 1.7 ml (kg body
mass)−1, which resulted in a lower increase in COHb than that in the
control groups (Figure 1a). To counteract a possible lower accuracy of
the calculated Hbmass owing to a smaller difference in COHb after
inhalation, we increased the number of replicate measures from six to
nine for the baseline value and to 12 for the post-inhalation value using
the four blood samples obtained between 14 and 20min. The resulting
analytical error was∼1% (Alexander et al., 2011).
All patients and control subjects were asked whether they felt any
side-effects from the CO-rebreathing procedure; none of the subjects
complained ormentioned any discomfort.
The CO concentration in the air remaining in the spirometer after
cessationof the rebreathingperiodwas significantly lower for theCMS
patients than for the control groups. Given that CO is used as a routine
marker for lung diffusion (Salcedo Posadas, Villa Asensi, deMirMessa,
Sardón Prado, & Larramona, 2015), this indicates the absence of
diffusion barriers in the lung, as could be expected from the chronically
augmented pulmonary arterial constriction (Villafuerte & Corante,
2016) or multiple pulmonary arterial thrombi occurring in patients
with polycythaemia vera (Ahlgrim et al., 2014; Arias-Stella, 1971). This
finding, however, is in agreement with data from Groepenhoff et al.
(2012), hinting at even greater CO-diffusion capacity in CMS patients
than in subjects from near sea level. Therefore, we concluded that
CO application to CMS patients is not limited by any problems with
pulmonary diffusion.
4.2 CO diffusion tomyoglobin
When CO is inhaled and bound to haemoglobin, a small amount of CO
diffuses from the blood to extravascular spaces, i.e. mostly to myo-
globin (Bruce & Bruce, 2003). In the present study, we determined
the Hbmass by calculating the diffusion of CO from blood to myo-
globin with the fixed factors 0.2% min−1 (Schmidt & Prommer, 2005)
and 0.3% min−1 (Prommer & Schmidt, 2007) for inhaled CO and by
using the model from Chada and Bruce (2012). Until 12 min after
starting the inhalation, the threemethods showed very similar results;
thereafter, in all four groups, the factor 0.3% min−1 slightly under-
estimated the Hbmass, whereas the model of Chada and Bruce (2012)
slightly overestimated the Hbmass in the high-altitude subjects. Using
the factor of 0.2% min−1 yielded an Hbmass plateau for ≥30 min after
CO inhalation, providing the best fit for all the groups investigated
here.
Our calculation is, therefore, a strong approximation with low
measurement errorwhen applied to groups similar to those used in the
present study, but different CO-diffusion factors might be more valid
for other groups and patients.
F IGURE 5 Haemoglobinmass (Hbmass) before and
after withdrawal of 500ml of blood in four chronic
mountain sickness patients. Presented are the
individual values of Hbmassmeasured with the
modified CO-rebreathingmethod before and after the
bloodwithdrawal and the Hbmassmeasured before and
calculated after the bloodwithdrawal. On the right side,
themean values for themeasured and calculated loss of
Hbmass are demonstrated
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4.3 CO-mixing time
For healthy subjects, complete mixing of an inhaled CO bolus was
determined to occur within 6min (Prommer & Schmidt, 2007; Schmidt
& Prommer, 2005). Therefore, blood samples from minute 7 after CO
inhalation (mean from samples drawn atminutes 6 and 8) are routinely
used in the optimizedCO-rebreathingmethod to calculate theHbmass
(Prommer & Schmidt, 2007). This concept was criticized by Keiser
et al. (2013), who claimed that the mixing was not complete at this
timepoint, thereby leading to theoverestimationofHbmass.Complete
mixingof aCOboluswithhigh interindividual variationwas foundafter
10 min by Garvican et al. (2010) and Gore et al. (2006), but because
of only small differences compared with the findings of Prommer and
Schmidt (2007), the method was not modified for healthy subjects
from sea level. Both groups describing the extended period for mixing,
however, recommended checking themixing time for the investigation
of special populations.
In the present study, complete mixing was achieved after 6 min in
the control subjects from near sea level (Controls-BT) but complete
mixing was not achieved until 12 min in the CMS patients and control
subjects from high altitude. For the CMS patients, this delay might
be explained by the impaired haemodynamics owing to higher blood
viscosity (Kwaan & Wang, 2003) as a consequence of haematocrit
values ranging between 63 and 78%; this impairment probably results
in reduced peripheral and organ perfusion, as can be assumed from
the reduced blood flow velocity in CMS patients (Claydon et al.,
2005).
According to the model of Bruce and Bruce (2003), CO mixing
and CO distribution in the body depends on five compartments, four
of which are vascular: arterial blood, mixed venous blood, muscle
tissue and non-muscle tissue. The time for blood to pass through each
of these compartments and therefore to become mixed depends on
the volume of the compartment and the blood flow through each
compartment (Bruce&Bruce, 2003;Garvican et al., 2010). Despite the
higher blood volume (Claydon et al., 2004), cardiac output is decreased
in CMS patients (León-Velarde, Villafuerte, & Richalet, 2010; Maignan
et al., 2009); given the high viscosity of the blood and the low
perfusion rate in all compartments, the mixing time is prolonged. Pre-
mature sampling of either capillary or venous blood might therefore
yield spurious results that falsely inflate the COHb%. This results in
an underestimation of Hbmass, as presented in Figure 2 for blood
samples obtained until 12 min after bolus inhalation. A plateau for
the calculated Hbmass, indicating the occurrence of complete mixing,
was achieved in all patients by 14 min after CO inhalation. When
comparing Hbmass values for this plateau with values derived from
the established protocol, in which blood sampling occurs at 7 min,
the difference in Hbmass amounts to ∼100 g, which corresponds to
6.7% (Figure 3). Therefore, these data strongly suggest that the oCOR
method shouldbemodifiedwhen it is applied topatients suffering from
erythrocytosis.
A delayed mixing time was also observed in control subjects
from high altitude, who have haematocrit values between 46 and
58%. Although the difference in calculated Hbmass between the two
protocols was smaller (∼50 g), we recommend the modified protocol
for further investigation of subjects from high altitude.
A possibility for reduction of the mixing time might be to conduct
the CO-rebreathing tests in the supine position, in which increased
venous return from the lower extremities (e.g. Truijen, Bundgaard-
Nielsen, & Van Lieshout, 2010) andmore homogeneous lung perfusion
could facilitate COmixing.
4.4 Reliability and validity
Test–retest with the modified protocol was performed on subjects
from high altitude, i.e. CMS patients, patients with previous CMS
diagnoses who did not fulfil the criterion [Hb] >21 g dl−1 and control
subjects. As shown in Figure 4, the reliability was very good in all
groups, resulting in a TE of 1.6%. Similar TE values were also described
for CO-rebreathing tests at sea level [TE between 1.1 (Gore et al.,
2006) and 2.3% (Eastwood, Bourdon, Withers, & Gore, 2009)] and at
altitude [TE= 1.4% (Wachsmuth et al., 2013)], proving the reliability of
themodifiedmethodwhenapplied tohigh-altitudepopulations, similar
to the establishedmethod.
The validity of the modified method was checked by phlebotomy of
a known blood volume and known Hbmass. The difference between
the measured and calculated volumes (0.9%) was in the same range
as that reported by Schmidt and Prommer (2005) immediately after
a blood donation. Both the reliability and the validity of the modified
method for CMS patients showed that the quality of data was the
same as that achieved using the established CO-rebreathing method
for healthy subjects and patients at sea level. Unfortunately, we did not
determine validity after blood sampling at minutes 6–8, which could
have confirmed the prolongedmixing time in CMS patients.
4.5 Possible practical importance
As our preliminary data show, the mean Hbmass of CMS patients was
expanded twofold, and the individual Hbmasswas increased threefold,
compared with healthy subjects from sea level. This increase might
be accompanied by blood volume expansion, which in turn strongly
influences cardiovascular function via volume overloading and hyper-
viscosity. Similar pathophysiological mechanisms might exist in poly-
cythaemia vera, in which plasma volume is also frequently expanded,
which masks the high red cell volume (Spivak, 2019). The modified
CO-rebreathing method might therefore represent a simple tool for
diagnosing the degree of erythrocytosis and the risk of possible
negative consequences in CMS patients and in patients with poly-
cythaemia of other origins, e.g. polycythaemia vera.
4.6 Conclusions
Application of the CO-rebreathing method to CMS patients and
healthy residents from high altitude (3600–4100 m a.s.l.) requires
modification of the established CO-rebreathing method. Although CO
uptake in the lungs and CO diffusion from blood to myoglobin are
similar between CMS patients and healthy subjects from sea level, the
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CO-mixing time is considerably delayed. If this delay is considered for
blood sampling after CO inhalation, the reliability and validity of the
modifiedmethod are as good as those of the establishedmethod; thus,
themodifiedmethod can be used to investigate patients suffering from
CMS or from other forms of polycythaemia.
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